1-3 of 3
Henk-André Kroon
Close
Sort by
Journal Articles

Safety, Tolerability, and Clinical Pharmacology of ANX009, an Inhibitory Antibody Fab Fragment Against C1q, Administered Subcutaneously to Healthy Volunteers

Anita Grover, Jeffrey Teigler, Emily Radomile, Shawn Rose, Ted Yednock, Sanjay Keswani, Henk-Andre Kroon
Journal: Blood
Blood (2021) 138 (Supplement 1): 3166.
https://doi.org/10.1182/blood-2021-153289
Published: 2021
Journal Articles

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Clinical Trials & Observations
Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, Luke Coyle, Carlos de Castro, Chieh-Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, Henk-André Kroon, Russell P. Rother, Peter Hillmen
Journal: Blood
Blood (2008) 111 (4): 1840–1847.
https://doi.org/10.1182/blood-2007-06-094136
Published: 2008
Journal Articles

Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.

Robert A. Brodsky, MD, Petra Muus, MD, PhD, Ulrich Dührsen, DM, Anita Hill, MB, MD, Monica Bessler, MD, PhD, Steven Coutre, MD, Raquel De Paz, MD, Tibor Moskovits, MD, Ryotaro Nakamura, MD, Eric Van den Neste, MD, Alberto Zanella, MD, Kerry Quinn-Senger, PhD, Henk-Andre Kroon, MD, David Cella, PhD
Journal: Blood
Blood (2006) 108 (11): 3770.
https://doi.org/10.1182/blood.V108.11.3770.3770
Published: 2006